Looks like there is still a lot of growth potential for this drug. Their sales team has not reached 60% of prescribing doctors. So current sales are just from 40% of the docs reached by the sales team! Ken K indicated that based on his experience and for sales organizations of other companies, 60 sales reps are about the right size to reach 100% of docs. He and his new hire Joe Turgeon will reevaluate in a few months to see if 60 sales reps are reaching the prescribing doctors and revise the # of reps as needed.
Another analyst asked why will Fusilev sales will not drop off like it did several times previously and Raj noted that previously Fusilev was given special permission by the FDA to sell the drug due to shortage but now we are approved to sell it and it has its own J-code. In 2008 they were only allowed to sell it for 2 weeks, in 2009 for 2 months, in 2010 for 6 months; it was approved in April 2011 but from April to Sept they didn’t have a sales force. All of the generic crud drugs are lumped into one J-code. He also indicated that all the generics compete with themselves and not with Fusilev and they make so little that you almost expect problems with the crud drug.
I wonder if AF or his family member got cancer, if he want to take a generic anticancer drug that is not chemically the same and 'kinda sorta works the same as the brand name and sorta close in efficacy ".. Cancer is life and death, every single percent more in your favor matters.